Highbridge Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Highbridge Capital Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-36,562	Closed	-$170K	–	1942
2016 Q1	$170K	Buy	36,562 +24,012	+191%	+$95.8K	﹤0.01%	1364
2015 Q4	$63K	Buy	+12,550	New	+$59.6K	﹤0.01%	1438
2015 Q3	–	Sell	-79,303	Closed	-$791K	–	1957
2015 Q2	$791K	Buy	+79,303	New	+$850K	0.01%	795
2014 Q3	–	Sell	-21,505	Closed	-$331K	–	1455
2014 Q2	$331K	Buy	+21,505	New	+$305K	﹤0.01%	844
2013 Q4	–	Sell	-42,201	Closed	-$426K	–	1445
2013 Q3	$426K	Buy	+42,201	New	+$376K	﹤0.01%	927

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Highbridge Capital Management's KERX Position: Q2 2016 in Review

Highbridge Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 36,562 shares — an estimated $170K sold.

Highbridge Capital Management first reported a position in KERX in Q3 2013 and held it in 5 quarters. The position peaked at $791K in Q2 2015. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

Highbridge Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Highbridge Capital Management sold 36,562 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $170K.
Highbridge Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 5 quarters.
Highbridge Capital Management's Keryx Biopharmaceuticals Inc position peaked at $791K in Q2 2015.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Highbridge Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.